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Abstract
Background: Hypothermia is neuroprotective in some ischemia–reperfusion injuries. Ischemia–reperfusion injury
may occur with traumatic subdural hematoma (SDH). This study aimed to determine whether early induction and
maintenance of hypothermia in patients with acute SDH would lead to decreased ischemia–reperfusion injury and
improve global neurologic outcome.
Methods: This international, multicenter randomized controlled trial enrolled adult patients with SDH requiring
evacuation of hematoma within 6 h of injury. The intervention was controlled temperature management of hypothermia to 35 °C prior to dura opening followed by 33 °C for 48 h compared with normothermia (37 °C). Investigators
randomly assigned patients at a 1:1 ratio between hypothermia and normothermia. Blinded evaluators assessed
outcome using a 6-month Glasgow Outcome Scale Extended score. Investigators measured circulating glial fibrillary
acidic protein and ubiquitin C-terminal hydrolase L1 levels.
Results: Independent statisticians performed an interim analysis of 31 patients to assess the predictive probability
of success and the Data and Safety Monitoring Board recommended the early termination of the study because of
futility. Thirty-two patients, 16 per arm, were analyzed. Favorable 6-month Glasgow Outcome Scale Extended outcomes were not statistically significantly different between hypothermia vs. normothermia groups (6 of 16, 38% vs.
4 of 16, 25%; odds ratio 1.8 [95% confidence interval 0.39 to ∞], p = .35). Plasma levels of glial fibrillary acidic protein
(p = .036), but not ubiquitin C-terminal hydrolase L1 (p = .26), were lower in the patients with favorable outcome
compared with those with unfavorable outcome, but differences were not identified by temperature group. Adverse
events were similar between groups.
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Conclusions: This trial of hypothermia after acute SDH evacuation was terminated because of a low predictive probability of meeting the study objectives. There was no statistically significant difference in functional outcome identified between temperature groups.
Keywords: Hypothermia (induced), Hematoma (subdural), Brain injuries (traumatic)

Introduction
Nearly 2.88 million Americans sustain a traumatic brain
injury (TBI) annually, and of them 56,800 die and 90,000
remain permanently disabled [1, 2]. Brain damage as a
result of TBI is caused by the primary injury and multiple
secondary pathological processes that occur as a result
of the initial trauma [3]. Although there is no cure for
the primary injury at present, there is ongoing work to
develop neuroprotective treatments to prevent and attenuate secondary injury. Early hypothermia is one modality shown to be neuroprotective in ischemia–reperfusion
injuries, such as in preclinical TBI models [4, 5], after
cardiac arrest [6–8], and in infants with hypoxic-ischaemic encephalopathy [9, 10]. However, clinical trial results
on the effect of hypothermia on outcome after TBI have
not proven efficacy [11–13].
Retrospective subgroup analysis of the National Acute
Brain Injury Study: Hypothermia I [14] and II [15] hypothermia trials revealed that patients with TBI who were
treated with hypothermia undergoing surgical evacuation
of intracranial hematomas had significantly improved
neurologic outcomes compared with patients treated
with normothermia [16]. We hypothesized that therapeutic hypothermia, when applied to a more homogeneous population of patients after subdural evacuation,
would improve clinical outcomes by preventing secondary pathological processes from ischemia–reperfusion
injury.
We performed a randomized controlled prospective
trial to study the effect of early therapeutic hypothermia in patients undergoing surgical evacuation of acute
subdural hematomas (SDH), called “Hypothermia for
Patients requiring Evacuation of Subdural Hematoma:
a Multicenter, Randomized Clinical Trial,” the “HOPES
Trial.” The primary objective of the study was to determine whether rapid induction of hypothermia prior to
emergent craniotomy for traumatic SDH would improve
outcome, as measured by Glasgow Outcome Scale
Extended (GOSE) at 6 months. Secondary objectives
were to assess the safety of intravascular cooling in the
management of SDH and to explore the effect of hypothermia on TBI plasma biomarkers, glial fibrillary acidic
protein (GFAP) and ubiquitin C-terminal hydrolase
L1 (UCH-L1) [17, 18]. GFAP, an astroglia marker, and
UCH-L1, a neuronal marker, are known to be elevated
within hours after TBI [19–21]. GFAP and UCH-L1 have

successfully detected lesions visible on head computed
tomography [19].

Methods
Participants

This was a prospective, pragmatic, randomized, controlled, multicenter trial to assess the safety and efficacy of intravascular cooling to induce hypothermia in
patients with TBI prior to and after surgical evacuation
of SDH. The trial enrolled adult (22–65 years of age)
patients with TBI within 6 h of SDH who were not following commands (Glasgow Coma Scale [GCS] motor
score ≤ 5). Patients were excluded if there was no
planned evacuation of the SDH, concomitant injury or
history contraindicated hypothermia for patient safety,
arrival temperature was < 35 °C, total GCS = 3 and
the patient had fixed and dilated pupils, or there was
an inability to obtain consent or use the exception to
informed consent for emergency research. Investigators
at tertiary care medical centers in the United States and
Japan enrolled patients under institutional review board
approved protocols.
Intervention

Patients were randomly assigned into two groups. The
intervention group received rapid induction of hypothermia to 35 °C followed by maintenance at 33 °C for 48 h
up to 5 days. Rewarming occurred at a rate of 0.25 °C/h.
Cooling and rewarming interventions were based on
recommendations from Clifton et al. [15]. If intracranial
pressure (ICP) increased during rewarming temperature
was held constant, and rewarming resumed after standard ICP control measures were instituted. The control
group received standard care, including temperature
maintenance at normothermia (37 °C) for 48 h. Temperature variations of ± 0.5 °C were permissible. Warming
of control patients prior to surgery is per standard care.
Standard care for rewarming is to warm patients slowly,
based on prior indications of poor outcome due to rapid
rewarming [14, 22]. Intravascular catheters (Thermogard XP System with Quattro catheter; ZOLL Circulation Inc, San Jose, CA) and fever control were used for
hypothermia and to maintain normothermia, as it has
been established that fever is detrimental in patients with
TBI [23–25]. Intravascular temperature management has
previously been shown to reach the target temperature
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rapidly and safely [26–28]. Shivering was managed
according to an established protocol used by the intensive care units [29]. Other care was at the discretion of
the treating physicians. All centers’ practice incorporated
the Brain Trauma Foundation Guidelines [30].

non-informative Beta (0.5, 0.5) prior distributions on the
parameters. Results were provided only to the DSMB
who gave a recommendation regarding trial continuance
based on the totality of the evidence.

Outcomes

To reduce the likelihood of imbalance of important prognostic factors between centers the study used a blocked
randomization scheme that randomized equally at a
1:1 ratio to hypothermia versus control normothermia.
Randomization was generated using a computer program by the independent statistical team who provided
sites sequentially numbered sealed opaque envelopes.
Once eligibility was confirmed site study physicians and
nurses enrolled participants, opened the randomization
envelope and assigned the participants to the designated
intervention.

Neuropsychological assessment of patients’ level of
recovery was performed at 4 weeks and 6 months
post-injury by investigators who were unaware of the
treatment group assignment. Dichotomized GOSE at
6 months post-injury was the primary outcome [31].
Good recovery and moderate disability were designated
as favorable outcomes; and severe disability, vegetative state, and death were designated as poor outcomes.
GOSE is a widely used global outcome score with good
interater and intrarater reproducibility [31]. GOSE
assesses consciousness, independence, work status, and
return of lifestyle via a structured interview.
Design

The trial design aimed for N = 120 patients and allowed
for an extension up to 350 patients. The design included
multiple interim analyses after 60, 120, 180 and 240
patients were randomized. At each interim analysis,
Bayesian predictive probabilities were to be used to
determine whether enrollment should stop for either
success or futility before the maximum enrollment. The
operating characteristics of the study design (type I error,
power, and expected sample size) were computed by
simulation in a variety of possible scenarios. Treatment
effect was based on data from Clifton et al. [16]. The trial
had power greater than 90% for a scenario where the proportion of 6-month GOSE score is good in the treatment
arm was 0.604 compared to 0.347 in the control arm and
the trial was quite likely to stop at or before the N = 120
interim analysis for success. Type I error was controlled
at 0.025 and the trial was quite likely to stop for futility at
or before the N = 120 interim analysis.
Due to slow accrual, an early futility interim analysis
was added to occur after N = 31 participants had completed 6-month follow-up. Enrollment continued during
this analysis, but decisions would be based on the data for
the initial 31 patients. This analysis computed the probability of success (probability of statistically significantly
higher rate of favorable GOSE in the hypothermia arm)
after enrollment of 60 patients, which was then viewed
as the absolute maximum feasible sample size given the
slow accrual. Predetermined stopping guidelines dictated
that if the predictive probability of success with a sample size of 60 patients was less than 0.40, the trial was
to stop for futility. This predictive probability was calculated based on Beta-Binomial distributions and used

Randomization

Blinding

Participants and clinical care providers were not blind
to assignment. Investigators were unaware of treatment
assignments and outcomes of other sites’ patients. Outcomes assessors were blinded to the patients’ treatment
arm.
Enzyme‑Linked Immunosorbent Assays

Investigators used enzyme-linked immunosorbent assays
(ELISA) to evaluate the plasma levels of GFAP and UCHL1 on the 24 patients with blood samples (13 hypothermia, 11 normothermia) that were available at three time
points. Time 1 (T1) was collected at less than 6 h post
TBI and precooling. T2 was collected 6 to 48 h post TBI
(within the time of temperature management); and T3
was collected 5 to 14 days post TBI (post cooling). Control standards and samples from six healthy volunteers
were measured. Blood was collected in K2 EDTA vacutainer tubes (BD, Franklin Lakes, NJ), processed within
an hour of draw and frozen at − 80 °C. The concentration of GFAP was measured using a sandwich enzyme
immunoassay (BioVendor, Ashville, NC) according to
manufacturer’s instructions. The lower limit of detection
for this assay is.045 ng/mL. UCH-L1 sandwich ELISAs
were developed using the UCH-L1 DuoSet ELISA (R&D
Systems, Minneapolis, MN). The lower limit of detection
for the UCH-L1 ELISA was 19.5 pg/mL. All samples were
analyzed in duplicate.
Adverse Events

A secondary objective was to evaluate the safety of intravascular cooling in the management of acute traumatic
SDH. Adverse events were monitored for the 6-month
study period. Serious adverse events were graded according to the United States Department of Health and
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Human Services (USDHHS) Common Terminology Criteria for Adverse Events V4.0 [32]. Predefined adverse
events of interest that were of concern with hypothermia
treatment were selected to be monitored and reported
regardless of grade. These included cardiac arrhythmias,
thromboembolic events, pneumonia, bleeding/hemorrhage, infection (culture positive, e.g., blood stream infection, urinary tract infection, ventriculitis), and death.
An independent DSMB consisting of a neurosurgeon,
a critical care physician and a statistician all of whom
are experts in the fields of TBI and hypothermia monitored the study. The study was registered on ClinicalTrials.gov as NCT02064959 and UMIN000014863 in
Japanese UMIN Clinical Trials Registry. The exception to
informed consent for emergency research provision was
used if permitted by the local institutional review board
and local law. Berry Consultants performed the statistical
design and independent statistical analysis.
Statistical Methods

The analysis was performed using a modified intent-totreat population of all randomly assigned patients having no exclusion criteria. Demographic and baseline data
were summarized using means, standard deviations,
or count and percentage. Adverse events are reported
by type, temperature group and frequency. Descriptive
data comparing groups were tested for normality using
the Shapiro–Wilk test and analyzed using Student’s
t-test and reported as means and standard deviation, or
if not normally distributed, using the Mann–Whitney
Rank Sum test and reported as medians and interquartile ranges (IQR). A one-sided Fisher’s exact test with a
predefined significance level of p < 0.02 to compare proportions of patients with good outcomes as measured by
GOSE at 6 months is reported as the primary outcome.
ELISA data were log transformed to normalize values
and analyzed using two-way repeated measures analysis
of variance (ANOVA). The ELISA analyses were exploratory, and significance was assessed at the.05 level.

Results
Patients (n = 34) were recruited between May 2014 and
July 2018, two were excluded from the study after randomization, but prior to intervention because they met
exclusion criteria (Fig. 1). Enrolled patients (n = 32) were
followed for 6 months with the last patient completing follow-up in February 2019. The trial was stopped
for futility after interim analysis of 31 patients showed
that the trial would not be likely to reach a decisive outcome when 60 patients completed the study (predictive probability of success at N = 60 was 1.64%). After
the trial ended and data were cleaned, one participant’s
6-month outcome was corrected and the last patient’s

outcome was included. Note that the predictive probability calculation was performed prior to finalization of
data. Favorable GOSE at 6 months did not differ between
hypothermia and control groups (6/16, 38% vs. 4/16, 25%;
odds ratio [OR] of 1.8, 95% confidence interval [CI] 0.39
to ∞, p = 0.35, respectively). Figure 2 illustrates ordinal
data of 6-month GOSE outcome by treatment group
(Fig. 2). A post hoc analysis adjusting for key covariates
(age, GCS motor score and pupillary response) did not
change the study results.
Demographics are similar between treatment groups
(Table 1). All patients had a GCS motor score < 6 (not
following commands) and were classified as moderate to
severe TBI. SDH was present in all patients and hematoma volumes and midline shift on the presurgical head
computed tomography scan were not different between
normothermia and hypothermia groups.
Temperature was not different between groups on
arrival (36.7 °C [IQR 36.15–36.98 °C] hypothermia group
and 36.15 °C [IQR 35.70–36.78 °C] normothermia group,
p = 0.2). Temperature at the time of dura opening was
lower for the hypothermia group 35 °C (IQR 34.99–
35.08 °C) compared with 35.95 °C (IQR 35.1–36.5 °C)
for the normothermia group (p = 0.004). Four patients
were unable to have the venous catheter placed prior to
surgery; two of these were in the hypothermia group.
The treating physicians decided not to cool these two
patients. One of them did not reach 35 ± 0.5 °C at the
time of the dura opening. Six patients in the normothermia group were within the hypothermia temperature
range (< 35.5 °C) at the time of dura opening and were
being warmed per standard care per protocol. Treating
physicians actively rewarmed one patient who was hemodynamically unstable at 24.8 h instead of 48 h.
Ancillary Analyses

There were 14 of 16 patients managed per intent at
hypothermia. Figure 3 displays the variance of time
from injury to hypothermia induction, maintenance and
rewarming compared to the mean daily low temperature
of the normothermia group (Fig. 3).
Intensive care and hospital length of stay data were
available for all but one patient with normothermia.
Intensive care unit length of stay did not differ between
groups, 12.95 days (IQR 9.2–17.7) hypothermia versus
11.4 days (IQR 7.95–32.4) normothermia (p = 0.7). Hospital length of stay was not different between hypothermia and normothermia groups 20.7 (IQR 17.8–29.8)
versus 18.2 (IQR 8.2–45.8) days, p = 0.9, respectively.
To examine whether differences in clinical variables
explain the lack of differences in outcome in our treatment groups, post hoc analysis of blood pressure, ICP,
blood gases, and blood glucose levels was performed.
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CONSORT 2010 Flow Diagram

Enrollment

Assessed for eligibility (n=2568)
Excluded (n=2534)
Not meeting inclusion criteria (n=2143)
 Exclusion Criteria (n=370)
 Declined/no consent to participate (n=21)


Randomized (n=34)

Allocated to normothermia (n=18)
 Received allocated intervention (n=16)

Allocation
Allocated to hypothermia (n=16)
 Received allocated intervention (n=14)

Did not receive allocated intervention (excluded
after randomization: SCI, INR>1.4 (n=2)
Catheter not placed or time/temperature range
differed (n=4)




Did not receive allocated intervention
(catheter not placed) (n=2)

Follow-Up
Lost to follow-up (give reasons) (n=0)

Lost to follow-up (give reasons) (n=0)

Discontinued intervention (give reasons) (n=0)

Discontinued intervention early
(hemodynamically unstable (n= 1))

Analysis
Analysed (n=16)
Excluded from analysis (excluded prior to
treatment SCI, INR>1.4) (n=2)


Analysed (n=16)
 Excluded from analysis (n=0)

Fig. 1 CONSORT flow diagram. Investigators screened 2568 patients for study eligibility. Of these, 2534 were excluded for not meeting enrollment
criteria. This included 2143 who did not meet inclusion criteria: there was no SDH or no evacuation planned (n = 749), age > 65 years or < 22 years
(n = 956), arrival was outside of time window (n = 231) or the patient was following commands (n = 207). Additionally, 370 people met exclusion
criteria by having GCS = 3, fixed and dilated pupils or duret hemorrhage (n = 144), known preexisting neurological deficit (n = 103), other contraindication to hypothermia (n = 108), arrival temperature < 35 °C (n = 6), spinal cord injury (n = 4), prisoner (n = 4), pregnant (n = 1), or an inability to
obtain consent, use exception from informed consent or declined to participate (n = 21). GCS, Glasgow Coma Scale; INR, international normalize
ratio; SDH, subdural hematoma
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blood glucose levels were examined by treatment group
over 8 days post TBI. We observed no group differences
in these clinical variables (Supplementary Fig. 1).
Harms

Fig. 2 Six-month GOSE score by treatment group. Post hoc analysis
of the percentage of patients by treatment group within each GOSE
grade. Primary outcome analysis separated favorable from unfavorable between Grade 4, upper severe disability and Grade 5, lower
moderate disability

Adverse events are summarized as serious adverse events
(Table 2) and other, not serious adverse events (Table 3).
There was no difference in the number of adverse events
per participant by treatment group, 4.5 (IQR 25–9)
events per normothermia participant versus 4 (IQR
2–7.8) events per hypothermia participant (p = 0.7). In
the normothermia group, 5 of 16 (31%) patients experienced new or increased bleeding. These included one
with worsening swelling and hemorrhage during surgery
and, post-operatively, two with epidural hematomas, one
with intracranial hemorrhage, and one with a worsening contusion. There was no new or increased bleeding
observed in the hypothermia treatment group.

Daily high and low mean arterial pressure (MAP), mean
partial pressure of carbon dioxide, mean ICP, and mean
Table 1 Demographics
Descriptor

Normothermia control
(n = 16)

Hypothermia (n = 16)

Total (n = 32)

Sex
Male

14

11

25 (78%)

Female

2

5

7 (22%)

41.2 ± 12.7

46.6 ± 15.1

43.9 ± 14.0

Average age, SD (yr)
Ethnicity
Hispanic

3

4

7 (22%)

Not Hispanic

13

11

24 (75%)

Unknown

0

1

1 (3%)

Race
White

10

10

20 (63%)

Asian

5

4

9 (28%)

Black/African American
Average height (cm)
Average weight (kg)
GCS score on arrival
Hematoma volume (cm3)
Midline shift
Diffuse axonal injury

1

2

3 (9%)

172 ± 7.1

168.5 ± 13.3

170.2 ± 10.6

80.4 ± 19.9

77.2 ± 18.1

78.8 ± 18.8

6.2 ± 2.6

6.5 ± 2.1

6.3 ± 2.3

9.2 ± 4.9

7.8 ± 3.9

8.5 ± 4.4

50.5 ± 23.6

45.9 ± 24.8

48.2 ± 23.9

Present

4 (25%)

2 (13%)

6 (19%)

Indeterminate

3 (19%)

3 (19%)

6 (19%)

Absent

9 (56%)

10 (63%)

19 (59%)

Not documented

0

1 (3%)

1 (3%)

Abnormal pupils

8 (50%)

Time to hypothermia induc- 4.0 ± 3.1
tion or reaching normothermia (h)
GCS Glasgow coma scale, SD standard deviation

9 (56%)

17 (53%)

4.8 ± 2.5

4.3 ± 2.9
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6-month GOSE outcomes of 1.64%, below the prespecified threshold indicating the trial should stop for futility. The final analysis of 32 patients completing their
6 months follow-up showed that a significant difference
in GOSE at 6 months between treatment groups could
not be detected.
Outcomes

Fig. 3 Variance in time for therapeutic temperature management.
Figure 3 displays the time variance from injury to induction of hypothermia, maintenance, and rewarming. The graph represents the 14
of 16 patients with hypothermia who had catheters placed and were
treated with hypothermia and 16 of 16 patients with normothermia.
The temperature of the hypothermia treatment group is compared to
the mean daily low temperature of the normothermia group

ELISA

At T1, median plasma GFAP and UCH-L1 levels of
patients with SDH were elevated compared to healthy
controls. GFAP levels at T1 were 3.39 (IQR 1.35–8.66)
ng/mL compared with 0 (IQR 0–0.12) ng/mL for healthy
comparators (p < 0.001). UCH-L1 levels at T1 were 1.07
(IQR 39–1.82) ng/ml compared to 0 ng/mL for healthy
comparators (p < 0.001). When separating the patients
by outcome group, two-way repeated measures ANOVA
indicated that GFAP (p = 0.036) [but not UCH-L1
(p = 0.26)] levels were lower in the patients with favorable outcome compared with those with unfavorable
outcome. The T1 samples showed higher levels of these
biomarkers as compared to the levels in T2 or T3 samples
(Fig. 4a GFAP and b UCH-L1). Separating the biomarker
results by temperature group, plasma levels of both
GFAP and UCH-L1 were elevated within the first 6 h of
injury (T1) and were significantly higher at T1 compared
with T2 and T3. However, two-way ANOVA analysis
indicated that neither marker differed by temperature
group (Fig. 4c and d). Thus, an effect from the hypothermia treatment on GFAP and UCH-L1 levels cannot be
identified in these samples.

Discussion
The Hypothermia for Patients requiring Evacuation of
Subdural Hematoma study was terminated early due to
futility. An interim analysis for futility resulted in a predictive probability of trial success once 60 patients have

Our statistical design planned for enrollment of 120
patients. Therefore, conclusions on the 32 patients must
be interpreted with the understanding that our sample size is a limitation. A recent meta-analysis of severe
TBI hypothermia trials that utilized protocols similar to
the one used in the present study indicated a reduced
death rate in those treated with hypothermia (33–35 °C)
compared with no cooling (OR = 0.627, p = 0.05) [33].
Although we also had fewer deaths in the hypothermia
group, the number of those surviving with good recovery did not differ between groups. We could not verify
the protective effect of hypothermia observed in post
hoc analysis of National Acute Brain Injury Study: Hypothermia I and II data; however, our results align with
the recent POLAR-RCT and Eurotherm3235 trials. The
international POLAR-RCT study which investigated prophylactic hypothermia in acute severe TBI demonstrated
no difference in favorable outcomes between hypothermia (48.8%) and normothermia (49.1%) patients (absolute risk difference, − 0.4, 95% CI, − 9.4 to 8.7; unadjusted
relative risk with hypothermia, 0.99, 95% CI, 0.82–1.19,
p = 0.94) [34]. The Eurotherm3235 trial evaluated the
effect of hypothermia on elevated ICP and 6-month
GOSE outcome after TBI. Eurotherm3235 ended early
on recommendation of their DSMB. Final analysis of a
dichotomized GOSE favored standard care (OR 1.74,
95% CI 1.09–2.77) [13].
Circulating Levels of GFAP and UCH‑L1

GFAP is an intermediate filament cytoskeletal protein
found primarily in astrocytes [35]. GFAP is released into
the circulation after TBI and early elevated GFAP levels
in the plasma are predictors of poor outcome [30]. Consistent with this, we demonstrated higher GFAP levels in
patients with poor outcome. UCH-L1, an abundant protein expressed in neurons, is involved in repair of injured
axons and neurons [36]. We did not detect an association
between UCH-L1 levels and outcome. Other studies have
supported GFAP as being superior to UCH-L1 at predicting outcome [37–39]. Circulating GFAP and UCH-L1
measured together are biomarkers for severe TBI [20,
40]. Consistent with previously published studies, our
patients’ plasma levels of GFAP and UCH-L1 were elevated within 6 h after injury and decreased to levels comparable to healthy comparators by T3 [19, 20].
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Table 2 Serious adverse events
Adverse event term

Organ system

Normothermia, Hypothermia,
count
count

Total, count

Anemia

Blood and lymphatic

6

4

10

Elevated white blood cell count

Blood and lymphatic

0

1

1

Sinus bradycardia

Cardiac

1

1

2

Tachycardia, agitation

Cardiac

1

0

1

Infection

GI

0

2

2

Mesenteric ischemia with lactic acid disorder (elevated)

GI

0

1

1

Cholecystitis, acute

Hepatobiliary

1

0

1

Acidosis

Metabolism and nutrition

0

1

1

Hyperglycemia

Metabolism and nutrition

1

0

1

Hypermagnesemia

Metabolism and nutrition

1

4

5

Hypernatremia

Metabolism and nutrition

4

1

5

Hypocalcemia

Metabolism and nutrition

1

0

1

Hypokalemia

Metabolism and nutrition

3

1

4

Hypophosphatemia

Metabolism and nutrition

4

2

6

Death

Nervous

5

3

8

Epidural hematoma

Nervous

2

0

2

Hospital readmission/facial droop

Nervous

0

1

1

Hydrocephalus

Nervous

2

0

2

Elevated intracranial pressure

Nervous

2

0

2

Intracranial hemorrhage

Nervous

1

0

1

Muscle weakness upper limb

Nervous

0

1

1

Neurological worsening

Nervous

0

1

1

Seizure

Nervous

1

0

1

Stroke

Nervous

5

1

6

Swelling and hemorrhage during surgery

Nervous

1

0

1

Worsening contusion

Nervous

1

0

1

Urinary tract infection

Renal and urinary

2

1

3

Laryngeal oedema

Respiratory

1

0

1

Acute respiratory distress syndrome

Respiratory

1

0

1

Hospital readmission/chest wall hematoma

Respiratory

1

0

1

Pneumonia

Respiratory

4

5

9

Pneumothorax

Respiratory

1

0

1

Sepsis

Respiratory

0

1

1

Vascular access complication

Surgical and medical procedures

0

1

1

Hypotension

Vascular

0

1

1

Thromboembolic event

Vascular

5

4

9

Serious adverse events were graded according to the USDHHS CTCAE V4.0. CTCAE grade 3 or higher were classified as severe adverse events
CTCAE, Common Terminology Criteria for Adverse Events, GI, gastrointestinal system, USDHHS, United States Department of Health and Human Services

To examine the effect of induced hypothermia on biomarker levels, we analyzed the plasma concentration
over time and did not see a group difference in GFAP
or UCH-L1 levels. Contrary to our findings, rodent
TBI models have demonstrated a reduction in UCHL1 levels with hypothermia treatment [41, 42]. However, after cardiac arrest UCH-L1 levels did not differ
between comatose patients with cardiac arrest maintained at 36 °C compared with those maintained at

33 °C [43]. Mondello et al. [44] reported higher serum
UCH-L1 levels in diffuse TBI compared with patients
with mass lesions (p = 0.01) and higher GFAP levels
in patients with mass lesions than those with diffuse
injury (p = 0.006). We do not have evidence for differing degrees of neuronal injury between our temperature groups. The hematoma size and amount of shift
were similar and diffuse axonal injury was absent in
comparable proportions of patients. However, it is
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Table 3 Other nonserious events
Adverse event term

Organ system

Normothermia,
count

Hypothermia,
count

Total, count

Anemia

Blood and lymphatic

4

4

8

CPK increased

Blood and lymphatic

1

0

1

Lymphocyte decreased

Blood and lymphatic

1

0

1

Sinus bradycardia

Cardiac

1

2

3

Supraventricular tachycardia

Cardiac

0

1

1

Fever

General

1

1

2

Constipation

GI

0

1

1

Diarrhea

GI

0

1

1

Blood bilirubin increased

Hepatobiliary

1

0

1

Liver dysfunction

Hepatobiliary

0

1

1

Lipase increased

Investigations

1

0

1

Acidosis

Metabolism and nutrition

0

1

1

Alkalosis

Metabolism and nutrition

1

1

2

Hypermagnesemia

Metabolism and nutrition

1

2

3

Hypernatremia

Metabolism and nutrition

2

2

4

Hypokalemia

Metabolism and nutrition

1

2

3

Hyponatremia

Metabolism and nutrition

0

1

1

Hypophosphatemia

Metabolism and nutrition

2

4

6

Wound infection

Musculoskeletal and connective tissue

0

1

1

Cranioplasty

Nervous

0

1

1

Hydrocephalus

Nervous

1

0

1

Seizure

Nervous

2

2

4

Brain abscess

Nervous

0

1

1

Meningitis

Nervous

0

1

1

Neurological worsening

Nervous

1

0

1

Pneumonia

Respiratory

3

6

9

Laryngeal oedema

Respiratory, thoracic, and mediastinal

0

1

1

Drug eruption

Skin and subcutaneous

0

1

1

Scalp wound/infection

Skin and subcutaneous

0

1

1

Wound drainage

Skin and subcutaneous

0

1

1

Replacement of catheter

Surgical and medical procedures

0

1

1

Hypotension

Vascular

0

1

1

Thrombus (superficial)

Vascular

1

0

1

Specific predefined adverse events of interest that historically were known to be of concern with hypothermia treatment were selected to be monitored and reported
regardless of grade. Those that were less than USDHHS CTCAE V4.0 grade 3 and other reported nonserious events are listed
CPK, Creatine phosphokinase, CTCAE, Common Terminology Criteria for Adverse Events, GI, gastrointestinal system, USDHHS, United States Department of Health and
Human Services

plausible that there were differing degrees of diffuse
injury between groups. It is also plausible that both the
hypothermia and protecting from fever with controlled
normothermia may have deterred pathological processes associated with diffuse injury.
Limitations

Our enrollment was slower than expected and resulted
in an insufficient sample size to meet our study objectives. Review of our enrollment criteria indicate the key
explanations for problems enrolling. Age limits (37%)

and lack of SDH or planned surgical evacuation (29%)
were the leading exclusion factors. Older age was associated with poorer outcome and more complications
in patients with TBI hypothermia [14] and after acute
SDH [45]. Younger ages (16–21 years) were excluded
from our study because they are classified as pediatric
patients by the United States Food and Drug Administration. The Brain Trauma Foundation Guidelines on
surgical management of acute SDH recommend surgical evacuation for (1) SDH with thickness > 10 mm or
midline shift > 5 mm and (2) on patients with SDH with
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Fig. 4 Plasma GFAP and UCH-L1 levels over time by outcome group and by temperature group. a Plasma levels of glial fibrillary acidic protein
(GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) were measured by enzyme-linked immunosorbent assay (ELISA). T1 GFAP levels were
elevated compared with T2 and T3 and patients with favorable outcome had significantly lower GFAP levels than those with unfavorable outcome,
p < .04. b T1 UCH-L1 levels were higher than T2 and T3 UCH-L1 levels, but no difference in UCH-L1 was detected between outcome groups, p = .26.
When samples were separated by temperature treatment groups the markers were elevated at T1 compared with T2 and T3. However, there was no
difference detected between hypothermia and normothermia treatment groups for GFAP levels, p = 0.28 (c) or UCH-L1 levels, p = 0.46 (d)

GCS < 9 or neurodeterioration of 2 or more points on
the GCS and/or asymmetric or fixed and dilated pupils
and/or ICP > 20 mmHg [46]. Patients who do not meet
these criteria may be observed closely and managed
non-operatively. If the patient neurologically deteriorates and/or a repeat head computed tomography indicates that the brain injury has worsened, the patient
will receive delayed surgery within 2–4 h of clinical
deterioration. Guidelines indicate that surgery performed 2–4 h after clinical deterioration result in superior outcome compared to delayed surgery.
We have learned that a large proportion of patients
with acute SDH do not meet Brain Trauma Guidelines
criteria for surgical intervention. A retrospective chart
review revealed that 646 of 869 (74.3%) of patients with
acute traumatic SDH at a major level I trauma center
were managed without surgical intervention. Only 6.5%
of these patients required a delayed surgical evacuation
at a median of 9.5 days after injury. GOS at discharge was
good in 77% of the non-operatively managed patients

[47]. Our criteria required that patients receive surgery
within 6 h of injury, and those patients requiring surgery
outside of this window would have been excluded.
More than 15% of patients with SDH were excluded
because they had non-survivable injuries, conditions
contraindicating hypothermia or consent could not be
obtained. Our enrollment criteria, based on previous
therapeutic hypothermia studies, while restrictive were
necessary for patient safety.
The study outcome was a general functional outcome,
GOSE at 6 months after injury. It is possible that a more
specific measure of cognitive function may have identified a treatment effect. GOSE is the current functional
outcome standard in TBI studies. Our findings may not
be generalizable to other centers with different management protocols. However, this was a multicenter,
pragmatic trial with protocols based on published recommendations for methods of therapeutic hypothermia.
We compared therapeutic hypothermia with controlled
normothermia. In previous studies [14–16, 22], standard
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care normothermia was not controlled with a device.
Controlled normothermia may have resulted in a smaller
variation in the first 48 h of the normothermia temperature range in our study and thus a potentially protective effect from early fever. A meta-analysis of 39 studies
including 14,431 patients indicated fever after neurological injury (traumatic, hemorrhagic, or ischaemic) is associated with worse outcome [48]. The future of targeted
temperature management in TBI may focus on tightly
controlled normothermia.

Conclusions
This randomized trial of hypothermia after acute SDH
was terminated due to a low predictive probability of
meeting the study objectives. At the interim futility analysis there was no difference identified between temperature groups in functional outcome. While the technology
for therapeutic hypothermia has advanced considerably
over the past 25 years facilitating ease of use and good
temperature control, the small percentage of patients
who met enrollment criteria may be indicative of the limited possibilities for further study in acute SDH. Hypothermia did not affect circulating levels of GFAP and
UCH-L1. Elevated plasma levels of GFAP and UCH-L1
within the first 6 h of TBI support the use of these proteins as biomarkers for TBI with SDH.
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